Gilead Sciences, Inc.
Price
Overview
Gilead Sciences, Inc. is a global biopharmaceutical enterprise, with operations spanning the United States, Europe, and numerous international markets. Its core mission involves discovering, developing, and commercializing innovative medications to address critical health needs. The company's extensive product portfolio encompasses treatments for a variety of severe conditions. For HIV/AIDS, it supplies key therapies such as Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, and Atripla. In response to the 2019 coronavirus pandemic, Gilead provides Veklury, an injectable drug for intravenous administration. Its offerings for liver diseases include Epclusa, Harvoni, Vosevi, Vemlidy, and Viread. Furthermore, Gilead assists patients battling hematological disorders, various cancers, and those undergoing cell therapy, through products like Yescarta, Tecartus, Trodelvy, and Zydelig. Other specialized medicines include Letairis, an oral drug for pulmonary arterial hypertension; Ranexa, also an oral medication, for chronic angina; and AmBisome, a liposomal formulation designed to combat serious invasive fungal infections. Gilead Sciences, Inc. actively engages in collaboration agreements with a diverse range of partners to advance its therapeutic pipeline. These include Arcus Biosciences, Inc., Pionyr Immunotherapeutics Inc., Tizona Therapeutics, Inc., Tango Therapeutics, Inc., Jounce Therapeutics, Inc., Galapagos NV, Janssen Sciences Ireland Unlimited Company, Japan Tobacco, Inc., Gadeta B.V., Bristol-Myers Squibb Company, Dragonfly Therapeutics, Inc., and Merck & Co, Inc. The company was founded in 1987 and its corporate headquarters are situated in Foster City, California.
Leadership
As Chief Executive Officer of Gilead Sciences, Inc., Daniel O'Day leads a biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines. Gilead is particularly recognized for its work in antiviral therapies, including treatments for HIV/AIDS and viral hepatitis, as well as its growing presence in oncology. The company’s mission is to advance transformative scientific breakthroughs that can help transform the care of patients with life-threatening diseases. Gilead’s portfolio spans a range of therapeutic areas, addressing significant unmet medical needs and striving to improve patient outcomes worldwide through its research and development efforts and strategic collaborations. Before assuming his current leadership position, O'Day accumulated extensive experience in the biopharmaceutical sector. He previously held senior executive roles at another major pharmaceutical company, where he oversaw significant segments of the business and contributed to the development and launch of numerous therapies. His career path reflects a deep understanding of the pharmaceutical industry, from research and development to commercial operations and global market strategy. This background has equipped him with a comprehensive perspective on the challenges and opportunities facing biotechnology and pharmaceutical organizations in bringing new treatments to patients. Under O'Day's leadership, Gilead Sciences has emphasized a strategy of strengthening its existing portfolio while aggressively pursuing expansion into new therapeutic areas, most notably oncology, through both internal innovation and strategic acquisitions. The company has also focused on leveraging its expertise in virology to address emerging public health challenges. Gilead is positioned today as a leading player in the biopharmaceutical landscape, navigating a dynamic market with a commitment to scientific advancement and a portfolio aimed at addressing serious diseases. The company continues to invest in the long-term growth potential of its pipeline and its ability to deliver value to patients and shareholders.
History & business model
This section is waiting to be written.
InvestWiki is community-edited. Contribute a plain-English history of Gilead Sciences, Inc., its business model, key products, and controversies.